The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Progress and challenges in viral vector manufacturing
Open accessAbstract
Promising results in several clinical studies have emphasized the potential of gene therapy to address important medical needs and initiated a surge of investments in drug development and commercialization. This enthusiasm is driven by positive data in clinical trials including gene replacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Amaurosis Type 2 and in cancer immunotherapy trials for hematological malignancies using chimeric antigen receptor T cells. These results build on the recent licensure of the European gene therapy product Glybera for the treatment of lipoprotein lipase deficiency. The progress from clinical development towards product licensure of several programs presents challenges to gene therapy product manufacturing. These include challenges in viral vector-manufacturing capacity, where an estimated 1-2 orders of magnitude increase will likely be needed to support eventual commercial supply requirements for many of the promising disease indications. In addition, the expanding potential commercial product pipeline and the continuously advancing development of recombinant viral vectors for gene therapy require that products are well characterized and consistently manufactured to rigorous tolerances of purity, potency and safety. Finally, there is an increase in regulatory scrutiny that affects manufacturers of investigational drugs for early-phase clinical trials engaged in industry partnerships. Along with the recent increase in biopharmaceutical funding in gene therapy, industry partners are requiring their academic counterparts to meet higher levels of GMP compliance at earlier stages of clinical development. This chapter provides a brief overview of current progress in the field and discusses challenges in vector manufacturing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
High-efficiency transformation of mammalian cells by plasmid DNA.
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,373
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Chen, C. A., & Okayama, H. (1988) · PubMed · Cited by 894
Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009
Pai, S.-Y., Logan, B. R., Griffith, L. M., Buckley, R. H., Parrott, R. E., Dvorak, C. C., Kapoor, N., Hanson, I. C., Filipovich, A. H., Jyonouchi, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401177 · Cited by 780
Baber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“While safety was reported in all trials, the clinical efficacy reported ranged from modest in Phase I/II clinical trials (25,27),”
ResultThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Gene therapy clinical trials worldwide to 2007—an update
Edelstein, M. L., Abedi, M. R., & Wixon, J. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1100 · Cited by 584
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Herzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Ylä-Herttuala, S. (2012) · Molecular Therapy · doi:10.1038/mt.2012.194 · Cited by 463
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A. J., Olivares, M. B., Schwartz, S. B., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 444
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404588 · Cited by 412
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M., Alvira, M., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 334
Testa, F., Maguire, A. M., Rossi, S., Pierce, E. A., Melillo, P., Marshall, K., Banfi, S., Surace, E. M., Sun, J., Acerra, C., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.048 · Cited by 330
Self-citationLipoplex morphologies and their influences on transfection efficiency in gene delivery
Ma, B., Zhang, S., Jiang, H., Zhao, B., & Lv, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.022 · Cited by 326
Grieger, J. C., Soltys, S. M., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.187 · Cited by 325
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267
Self-citationSmith, R. H., Levy, J. R., & Kotin, R. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.128 · Cited by 261
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
Self-citationJiang, H., Pierce, G. F., Ozelo, M. C., de Paula, E. V., Vargas, J. A., Smith, P., Sommer, J., Luk, A., Manno, C. S., High, K. A., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.004 · Cited by 207
Continuous high-titer HIV-1 vector production
Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F.-L., Mitrophanous, K., & Collins, M. (2003) · Nature Biotechnology · doi:10.1038/nbt815 · Cited by 198
Merten, O.-W., Charrier, S., Laroudie, N., Fauchille, S., Dugué, C., Jenny, C., Audit, M., Zanta-Boussif, M.-A., Chautard, H., Radrizzani, M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.060 · Cited by 185
Upscaling of lentiviral vector production by tangential flow filtration
Geraerts, M., Michiels, M., Baekelandt, V., Debyser, Z., & Gijsbers, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.778 · Cited by 167
Thornhill, S. I., Schambach, A., Howe, S. J., Ulaganathan, M., Grassman, E., Williams, D., Schiedlmeier, B., Sebire, N. J., Gaspar, H. B., Kinnon, C., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300393 · Cited by 166
Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J.-M., Hauck, B., Luna, J., Sommer, J. M., et al. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.11.019 · Cited by 160
Self-citationAnsorge, S., Lanthier, S., Transfiguracion, J. C., Durocher, Y., Henry, O., & Kamen, A. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1370 · Cited by 157
Broussau, S., Jabbour, N., Lachapelle, G., Durocher, Y., Tom, R. L., Transfiguracion, J. C., Gilbert, R., & Massie, B. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300383 · Cited by 156
Throm, R. E., Ouma, A. A., Zhou, S., Chandrasekaran, A., Lockey, T. D., Greene, M. R., Ravin, S. S. D., Moayeri, M., Malech, H. L., Sorrentino, B. P., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191049 · Cited by 154
Segura, M. M., Garnier, A., Durocher, Y., Coelho, H., & Kamen, A. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21467 · Cited by 147
Large-scale recombinant adeno-associated virus production
Kotin, R. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr141 · Cited by 137
New developments in lentiviral vector design, production and purification
Segura, M. M., Mangion, M., Gaillet, B., & Garnier, A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.779249 · Cited by 133
Transient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131
Self-citationKuroda, H., Kutner, R. H., Bazan, N. G., & Reiser, J. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2008.11.021 · Cited by 112
State‐of‐the‐art of the production of retroviral vectors
Merten, O. (2004) · Journal of Gene Medicine · doi:10.1002/jgm.499 · Cited by 111
Construction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108
Chadeuf, G., Ciron, C., Moullier, P., & Salvetti, A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.003 · Cited by 107
Thomas, D. L., Wang, L., Niamke, J., Liu, J., Kang, W., Scotti, M. M., Ye, G., Veres, G., & Knop, D. R. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.004 · Cited by 106
Cecchini, S., Virág, T., & Kotin, R. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.250 · Cited by 101
Durocher, Y., Pham, P. L., St‐Laurent, G., Jacob, D., Cass, B., Chahal, P. S., Lau, C. J., Nalbantoglu, J. N., & Kamen, A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.03.014 · Cited by 94
Complex Formation with Plasmid DNA Increases the Cytotoxicity of Cationic Liposomes
Nguyen, L. T., Atobe, K., Barichello, J. M., Ishida, T., & Kiwada, H. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.751 · Cited by 92
Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor
Valkama, A. J., Leinonen, H. M., Lipponen, E. M., Turkki, V., Malinen, J., Heikura, T., Ylä‐Herttuala, S., & Lesch, H. P. (2017) · Gene Therapy · doi:10.1038/gt.2017.91 · Cited by 89
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88
Self-citationManufacturing Recombinant Adeno-Associated Viral Vectors from Producer Cell Clones
Thorne, B. A., Takeya, R. K., & PELUSO, R. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.070 · Cited by 80
Rexin-G, a targeted genetic medicine for cancer
Gordon, E. M., & Hall, F. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481666 · Cited by 79
Touzot, F., Moshous, D., Creidy, R., Neven, B., Frange, P., Cros, G., Caccavelli, L., Blondeau, J., Magnani, A., Luby, J.-M., et al. (2015) · Blood · doi:10.1182/blood-2014-12-616003 · Cited by 75
Virág, T., Cecchini, S., & Kotin, R. M. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.092 · Cited by 73
Slepushkin, V., Dropulić, B., Chang, N., Gan, Y., Jiang, B., Deausen, E., Berlinger, D., Binder, G. K., Andre, K., Humeau, L. M. P. F., et al. (2003) · BioProcessing Journal · doi:10.12665/j25.dropulic · Cited by 73
Kutner, R. H., Puthli, S., Marino, M. P., & Reiser, J. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-10 · Cited by 72
Comparison of Different Bioreactor Systems for the Production of High Titer Retroviral Vectors
Merten, O.-W., Cruz, P. E., Rochette, C., Gény-Fiamma, C., Bouquet, C., Gonçalves, D., Danos, O., & Carrondo, M. J. T. (2001) · Biotechnology Progress · doi:10.1021/bp000162z · Cited by 71
Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor
Wang, X., Olszewska, M., Qu, J., Wasielewska, T., Bartido, S., Hermetet, G., Sadelain, M., & Rivière, I. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000072 · Cited by 70
Comparison of Transfection Conditions for a Lentivirus Vector Produced in Large Volumes
Karolewski, B. A., Watson, D. J., Parente, M. K., & Wolfe, J. H. N. (2003) · Human Gene Therapy · doi:10.1089/104303403322319372 · Cited by 69
Farson, D. A., Harding, T. C., Tao, L., Liu, J., Powell, S., Vimal, V., Yendluri, S., Koprivnikar, K. E., Ho, K., Twitty, C., et al. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.622 · Cited by 67
Optimized Production of High-Titer Recombinant Adeno-Associated Virus in Roller Bottles
Liu, Y.-L., Wagner, K. A., Robinson, N., Sabatino, D. E., Margaritis, P., Xiao, W., & Herzog, R. W. (2003) · BioTechniques · doi:10.2144/03341dd07 · Cited by 66
Highly Efficient, Large Volume Flow Electroporation
Li, L., Shivakumar, R., Feller, S., Allen, C., Weiss, J. M., Dzekunov, S. M., Singh, V., Holaday, J. W., Fratantoni, J. C., & Liu, L. N. (2002) · Technology in Cancer Research & Treatment · doi:10.1177/153303460200100504 · Cited by 65
Wu, S., Huang, G. Y., & Liu, H. (2002) · Biotechnology Progress · doi:10.1021/bp020026p · Cited by 63
Galibert, L., & Merten, O. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.008 · Cited by 62
Chulay, J. D., Ye, G.-J., Thomas, D. L., Knop, D. R., Benson, J. M., Hutt, J. A., Wang, G., Humphries, M. R., & Flotte, T. R. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.118 · Cited by 60
Emmerling, V. V., Pegel, A., Milián, E., Venereo-Sánchez, A., Kunz, M., Wegele, J., Kamen, A. A., Kochanek, S., & Hoerer, M. (2016) · Biotechnology Journal · doi:10.1002/biot.201500176 · Cited by 60
Herzog, R. W. (2015) · Frontiers in bioscience · doi:10.2741/4324 · Cited by 59
Hildinger, M., Baldi, L., Stettler, M., & Wurm, F. M. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9441-3 · Cited by 57
Scalable production of adeno‐associated virus type 2 vectors via suspension transfection
Park, J. Y., Lim, B., Lee, K., Kim, Y. K., & Jo, E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20776 · Cited by 53
Greene, M. R., Lockey, T. D., Mehta, P. K., Kim, Y., Eldridge, P. W., Gray, J. T., & Sorrentino, B. P. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.150 · Cited by 50
Toward exascale production of recombinant adeno-associated virus for gene transfer applications
Cecchini, S., Negrete, A., & Kotin, R. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.61 · Cited by 50
Clinical Development of Oncolytic Viruses in China
Liang, M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958760 · Cited by 49
Stornaiuolo, A., Piovani, B. M., Bossi, S., Zucchelli, E., Corna, S., Salvatori, F., Mavilio, F., Bordignon, C., Rizzardi, G. P., & Bovolenta, C. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.190 · Cited by 47
Negrete, A., & Kotin, R. M. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.05.020 · Cited by 47
Manufacturing of viral vectors for gene therapy: part I. Upstream processing
Merten, O.-W., Schweizer, M., Chahal, P. S., & Kamen, A. (2014) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.14.16 · Cited by 45
Lesch, H. P., Heikkilä, K., Lipponen, E. M., Valonen, P. K., Müller, A., Räsänen, E., Tuunanen, T., Hassinen, M. M., Parker, N. R., Karhinen, M., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.081 · Cited by 44
Ozuer, A., Wechuck, J., Goins, W. F., et al. (2002) · Biotechnology and Bioengineering · doi:10.1002/bit.10162 · Cited by 44
Rourou, S., van der Ark, A., Majoul, S., et al. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2064-y · Cited by 43
Enhancement of calcium phosphate-mediated transfection by inclusion of adenovirus in coprecipitates
Lee, J. H., & Welsh, M. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300857 · Cited by 41
Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Wright, J. F., Wellman, J. A., & High, K. A. (2010) · Current Gene Therapy · doi:10.2174/156652310793180715 · Cited by 37
Self-citationVector characterization methods for quality control testing of recombinant adeno-associated viruses
Wright, J. F., & Zelenaia, O. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-095-9_11 · Cited by 34
Self-citationvan der Loo, J. C. M., Swaney, W. P., Grassman, E., Terwilliger, A., Higashimoto, T., Schambach, A., Baum, C., Thrasher, A. J., Williams, D. A., Nordling, D. L., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.102 · Cited by 34
Przybylowski, M., Hakakha, A., Stefanski, J., Hodges, J., Sadelain, M., & Rivière, I. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302648 · Cited by 34
(2004) · CRC Press eBooks · doi:10.3109/9780203026656-2 · Cited by 32
Wikstrom, K. I., Blomberg, P., & Islam, K. B. (2004) · Biotechnology Progress · doi:10.1021/bp030065g · Cited by 31
More on influenza vaccine in young children.
Sancho, A., Melchiorri, D., & Abadie, E. (2012) · PubMed · doi:10.1056/nejmc1205643 · Cited by 22
Retroviral vector production in the National Gene Vector Laboratory at Indiana University
Cornetta, K., Matheson, L., & Ballas, C. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302613 · Cited by 22
Guy, H. M., McCloskey, L., Lye, G. J., Mitrophanous, K. A., & Mukhopadhyay, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.200 · Cited by 19
Investor Outlook: Focus on Upcoming LCA2 Gene Therapy Phase III Results
Schimmer, J., & Breazzano, S. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.29001.sch · Cited by 18
Nasimuzzaman, M., Kim, Y., Wang, Y., & Persons, D. A. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.20 · Cited by 16
Our journey to successful gene therapy for hemophilia B
Nathwani, A. C., Nienhuis, A. W., & Davidoff, A. M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2540 · Cited by 15
Hu, P., Li, Y., Sands, M. S., McCown, T. J., & Kafri, T. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.25 · Cited by 15
van der Loo, J. C. M., Swaney, W. P., Grassman, E., Terwilliger, A., Higashimoto, T., Schambach, A., Hacein‐Bey‐Abina, S., Nordling, D., Cavazzana, M., Thrasher, A. J., et al. (2012) · Gene Therapy · doi:10.1038/gt.2012.37 · Cited by 15
Progress towards gene therapy for haemophilia B
Patel, N., Reiss, U. M., Davidoff, A. M., & Nathwani, A. C. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1523-0 · Cited by 13
Gene therapies advance, but some see manufacturing challenges
Dolgin, E. (2012) · Nature Medicine · doi:10.1038/nm1212-1718 · Cited by 10
Feng, L., Guo, M., Zhang, S., et al. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070081 · Cited by 10
Tognon, M. G., Cattozzo, E. M., Bianchi, S., & Romanelli, M. G. (1996) · Virus Genes · doi:10.1007/bf00572959 · Cited by 10
Adeno-Associated Viral Vector Manufacturing: Keeping Pace with Accelerating Clinical Development
Wright, J. F. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.2514 · Cited by 10
Self-citation
Cited by
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Moradi, S., Mahdizadeh, H., Šarić, T., Kim, J., Harati, J., Shahsavarani, H., Greber, B., & Moore, J. B. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1455-y · Cited by 287
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Metadata
- Authors
- van der Loo, J. C. M., & Wright, J. F.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-30
- Volume
- 25
- Issue
- R1
- Pages
- R42-R52
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W1862365802
- Cited by
- 255
- References
- 113
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.